A Study of VLX1570 and Dexamethasone in Myeloma Patients
Terminated
This is a phase 1/2 single arm study to determine the safety and efficacy of VLX1570 IV infusion administered with low dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/03/2018
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Multiple Myeloma
Addition of Clonidine to Ropivacaine in Adductor Canal Block
Unknown
Total knee arthroplasty (knee replacement) is a common orthopedic procedure for osteoarthritis. This procedure is performed either under general anesthesia or spinal anesthesia; after the procedure in the recovery room, these patients undergo adductor canal block, which is a nerve block to provide 8-14 hours of postoperative pain control. For this nerve block, 15-20 ml of local anesthetic is combined with adjuvant medications to improve the quality of pain control as well as the duration of pain... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2018
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Postoperative Pain
Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome
Completed
Jeffrey Chang MD is conducting a research study to learn more about the increased male hormone levels, otherwise known as androgens, seen in women with polycystic ovary syndrome (PCOS). Women with PCOS have ovaries that are comprised of many cysts, or follicles. They also have irregular or absent menstrual periods and symptoms of increased male hormones, such as facial hair or acne. In each part of the study (except part 4 which is for PCOS women only) we will be comparing responses of PCOS wome... Read More
Gender:
FEMALE
Ages:
Between 18 years and 37 years
Trial Updated:
05/01/2018
Locations: UCSD Medical Center, San Diego, California
Conditions: Polycystic Ovary Syndrome
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
Terminated
This clinical trial is studying how well granisetron, aprepitant, and dexamethasone work in preventing nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or stage IV ovarian cancer. Granisetron patch, aprepitant and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or stage IV ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/24/2018
Locations: Sudarshan K Sharma MD Limted-Gynecologic Oncology, Hinsdale, Illinois +1 locations
Conditions: Nausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Stage II Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Ovarian Carcinoma
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Completed
The purpose of the study is to determine whether the addition of Elotuzumab to Bortezomib/ Dexamethasone will prolong the time before myeloma worsens \[progression free survival (PFS)\].
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2018
Locations: Compassionate Cancer Res Grp, Corona, California +76 locations
Conditions: Multiple Myeloma
Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures
Completed
Cortisol is a stress hormone that can be measured in saliva. This has provided a convenient way to evaluate the biological impact of day-to-day stressors that people encounter as they go about their lives, since saliva is so easy to collect. However, the biological meaning of saliva cortisol measures has never been carefully examined. The goal of this study is to collect saliva from a large group of people as they go about their every-day lives, to measure their cortisol levels, and then study t... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/19/2018
Locations: University of Michigan Health System, Ann Arbor, Michigan
Conditions: Stress
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
Completed
The goal of this clinical research study is to learn if intensive chemotherapy given over 6 months can help to control or cure Burkitt's leukemia, Burkitt's lymphoma, or small non-cleaved cell B-cell leukemia or lymphoma. Another goal is to see how well this treatment works when given with Rituximab. The safety of the combined treatment will also be studied.
Gender:
ALL
Ages:
All
Trial Updated:
04/18/2018
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Burkitt's Lymphoma, Burkitt'S-like Lymphoma
Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Completed
Migraines are a specific type of headache that frequently recur and are very painful. Although there are many medications that are effective against migraines, none of these medications cure 100% of migraines. Another problem with migraines is that although many times they get better after intravenous (IV) treatment in the emergency room (ER), about 1/3 of the time migraines recur the next day. The purpose of this research project is to see if adding a medication called dexamethasone to standard... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2018
Locations: Jacobi Medical Center, Bronx, New York +2 locations
Conditions: Migraine
Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)
Completed
This study will examine the use of the dexamethasone implant (Ozurdex) in patients with macular edema associated with an epiretinal or preretinal membrane requiring surgical intervention. After the surgery is performed (pars plana vitrectomy), an Ozurdex implant will be placed in the eye. Patients will be followed for 1 year.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/17/2018
Locations: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
Conditions: Diabetic Macular Edema, Epiretinal Membrane
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
Completed
The purpose of this study is to study the MRD status after VELCADE based induction therapy (VELCADE, lenalidomide, dexamethasone or VELCADE, liposomal doxorubicin, dexamethasone) in patients with previously untreated multiple myeloma and study the impact of HDC and ASCT on MRD status post-transplant. Our hypothesis is that MRD-status will continue to increase significantly at 3 months post-transplant and will validate that HDC and ASCT needs to be performed even when patients have achieved major... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2018
Locations: University of Tennessee Cancer Institute, Boston Baskin Cancer Group, Memphis, Tennessee +1 locations
Conditions: Multiple Myeloma
Treatment of Chronic Migraine Headaches.
Unknown
The purpose of the study is assessment of the safety and efficacy of the De-Novo therapy in the treatment of craniofacial neuralgia and migraine headaches.This is an open-label study of simultaneous administration of combination of dexamethasone, lidocaine, and thiamine into the trigeminal nerve branches as well as greater and lesser occipital nerve bilaterally in one session. Patients who meet the exclusion and inclusion criteria are eligible for trial if they have experienced chronic migraine... Read More
Gender:
ALL
Ages:
Between 10 years and 90 years
Trial Updated:
04/02/2018
Locations: Corona Doctors Medical Clinics Inc, Corona, California
Conditions: Chronic Migraine Without Aura, Intractable, Migraine With Typical Aura, Migraine Disorders
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Completed
Establishment of safety profile of HuMax-CD38 when given as monotherapy in participants with multiple myeloma relapsed from or refractory to at least 2 different cytoreductive therapies and without further established treatment options.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2018
Locations: Not set, Boston, Massachusetts +6 locations
Conditions: Multiple Myeloma